These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 29783321)

  • 1. Is premarket identification of hepatotoxic drugs and sensitive patients possible based on high-dimensional 'omic data?
    Kodell RL; Chen JJ
    Per Med; 2010 Mar; 7(2):171-178. PubMed ID: 29783321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An approach to identifying preclinical biomarkers of susceptibility to drug-induced toxicity.
    Lin WJ; Chen JJ
    Pharmacogenomics; 2011 Apr; 12(4):493-501. PubMed ID: 21521022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
    Utkarsh D; Loretz C; Li AP
    Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of drug-induced toxicity biomarkers for treatment determination.
    Lu TP; Chen JJ
    Pharm Stat; 2015; 14(4):284-93. PubMed ID: 25914330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational chemistry approach for the early detection of drug-induced idiosyncratic liver toxicity.
    Cruz-Monteagudo M; Cordeiro MN; Borges F
    J Comput Chem; 2008 Mar; 29(4):533-49. PubMed ID: 17705164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of potential genomic biomarkers of hepatotoxicity caused by reactive metabolites of N-methylformamide: Application of stable isotope labeled compounds in toxicogenomic studies.
    Mutlib A; Jiang P; Atherton J; Obert L; Kostrubsky S; Madore S; Nelson S
    Chem Res Toxicol; 2006 Oct; 19(10):1270-83. PubMed ID: 17040096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of in vitro protein biomarkers of idiosyncratic liver toxicity.
    Gao J; Ann Garulacan L; Storm SM; Hefta SA; Opiteck GJ; Lin JH; Moulin F; Dambach DM
    Toxicol In Vitro; 2004 Aug; 18(4):533-41. PubMed ID: 15130611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of hepatic transporters (MDR1 and MRP2) in inflammation-associated idiosyncratic drug-induced hepatotoxicity investigated by microvolume cytometry.
    Saab L; Peluso J; Muller CD; Ubeaud-Sequier G
    Cytometry A; 2013 Apr; 83(4):403-8. PubMed ID: 23401306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans?
    Zhang M; Chen M; Tong W
    Chem Res Toxicol; 2012 Jan; 25(1):122-9. PubMed ID: 22122743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of potentially hepatotoxic drugs among major US drug compendia.
    Guo JJ; Wigle PR; Lammers K; Vu O
    Res Social Adm Pharm; 2005 Sep; 1(3):460-79. PubMed ID: 17138490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Strategy for Screening and Application of Specific Biomarkers in Hepatotoxicity Using Metabolomics Combined With ROC Curves and SVMs.
    Li Y; Wang L; Ju L; Deng H; Zhang Z; Hou Z; Xie J; Wang Y; Zhang Y
    Toxicol Sci; 2016 Apr; 150(2):390-9. PubMed ID: 26781514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatic tolerance of atypical antipsychotic drugs].
    Dumortier G; Cabaret W; Stamatiadis L; Saba G; Benadhira R; Rocamora JF; Aubriot-Delmas B; Glikman J; Januel D
    Encephale; 2002; 28(6 Pt 1):542-51. PubMed ID: 12506267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A zebrafish phenotypic assay for assessing drug-induced hepatotoxicity.
    He JH; Guo SY; Zhu F; Zhu JJ; Chen YX; Huang CJ; Gao JM; Dong QX; Xuan YX; Li CQ
    J Pharmacol Toxicol Methods; 2013; 67(1):25-32. PubMed ID: 23128142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE
    Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatotoxicity of chemotherapeutic and oncologic agents.
    King PD; Perry MC
    Gastroenterol Clin North Am; 1995 Dec; 24(4):969-90. PubMed ID: 8749907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high content screening assay to predict human drug-induced liver injury during drug discovery.
    Persson M; Løye AF; Mow T; Hornberg JJ
    J Pharmacol Toxicol Methods; 2013; 68(3):302-13. PubMed ID: 23933113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Could idiosyncratic thinking fit with << omics >>?].
    Narjoz C; Beaune P; de Waziers I
    Med Sci (Paris); 2010; 26(6-7):641-6. PubMed ID: 20619168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker classifiers for identifying susceptible subpopulations for treatment decisions.
    Lin WJ; Chen JJ
    Pharmacogenomics; 2012 Jan; 13(2):147-57. PubMed ID: 22188363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver.
    Piñeiro-Carrero VM; Piñeiro EO
    Pediatrics; 2004 Apr; 113(4 Suppl):1097-106. PubMed ID: 15060205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.